Keros Therapeutics, Inc. (KROS) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

59NeutralDD: Jun 08, 2026Analyst: 68

paidReference price

USD 10.0 (08/06/2026)

domainMkt cap

$198.06M

pie_chartShares

19.79M

candlestick_chart52W

$9.79-$22.55

trending_downShort interest

8.5%

INFONASDAQHealth Care80 employeesFounded 2015

Verdict: Asymmetric — Cash-floor anchored

Trading at 72% of cash ($10.30 vs $14.22/sh net cash). $281.5M cash, zero debt, runway into 1H 2028. Hard floor + Takeda-funded elritercept Phase 3 (RENEW MDS dosed Jul 2025, myelofibrosis Ph3 planned) + rinvatercept DMD Phase 2 starting Q1'26 (FDA orphan drug status Aug 2025). Activist-driven $375M capital return completed Oct 2025 reset ownership. Main bear case: active class action investigations over Dec 2024 TROPOS halt (cibotercept PAH safety). Asymmetric setup: cash floor caps downside ~−10%, pipeline-funded upside ~+90% to mid-teens FV.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-06-08

Keros Therapeutics, Inc. (KROS)

Clinical-stage biopharma · NASDAQ · Lexington, MA

"Net-cash dislocation with funded catalysts; asymmetric setup conditional on pipeline progress and litigation resolution."

Cash > Mkt Cap Zero debt Class action open Takeda Phase 3 Cibotercept halted

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value — Cash Floor + risk-adjusted Pipeline NPV (rNPV-lite)

Fair value base case

USD 15.8

Range: USD 9.50-USD 25.0

Reference price: USD 10.0 (08/06/2026)

Base upside/downside: +58%

Methodology: rNPV-lite. Components are not blended; tabella is additive. Implicit valuation multiple: EV (Mkt Cap $204M − Cash $281M = -$77M) means market currently assigns negative value to pipeline + Takeda asset. FV of $15.80 implies EV ≈ +$103M (Pipeline+Takeda contracted), which is conservative vs Takeda's standalone investment in licensed compound. Cross-check: pure cash floor ($10.63) is 67% of FV — base case requires ~$5.20 of pipeline NPV to materialize, which Takeda is actively funding. Probability-weighted FV: 25%×$25 + 45%×$16 + 30%×$9 = $16.15 → consistent with $15.80 base. ⚠️ Not investment advice.

Component	Assumption	USD/share
End-FY26E net cash	$281.5M Q1'26 − 3×$23.7M burn = $210.4M / 19.79M sh	+10.63
Takeda elritercept (rNPV)	$200M risk-adj NPV (40% PoS × $500M peak royalties+milestones NPV) / 19.79M	+4.04
Rinvatercept (KER-065) option	DMD+ALS: 15% PoS × $250M NPV / 19.79M = $1.89; Phase 2 starting Q1'26	+1.89
Cibotercept residual	Halted in PAH; 5% prob × $100M repurposing value / 19.79M	+0.25
SBC dilution (12mo)	~4% dilution × $11 weighted price = $0.45 dilution; rounded	−0.45
Litigation reserve	Class action: $10M expected settlement / 19.79M	−0.56
FV base case	Sum: 10.63 + 4.04 + 1.89 + 0.25 − 0.45 − 0.56	≈ $15.80

Bull

$22–$28

Probability: 25%

Takeda elritercept Ph3 MDS shows efficacy signal, myelofibrosis Ph3 initiates; rinvatercept Ph2 DMD shows muscle-mass increase; partial capital return resumes. Re-rate to peer median 1.5x P/Cash + pipeline.

Base

$14–$18

Probability: 45%

Cash floor + Takeda partnership progresses on schedule; rinvatercept enrolls on time; class action settled at ~$10M. Market closes gap to net cash + Takeda asset.

Bear

$8–$10

Probability: 30%

Takeda Ph3 MDS interim disappoints OR new safety signal; rinvatercept Ph2 delays; class action settles at high end ($25M+); cash burn accelerates. Re-rate toward $9 wind-down floor.

Methodology: Methodology: rNPV-lite. Components are not blended; tabella is additive. Implicit valuation multiple: EV (Mkt Cap $204M − Cash $281M = -$77M) means market currently assigns negative value to pipeline + Takeda asset. FV of $15.80 implies EV ≈ +$103M (Pipeline+Takeda contracted), which is conservative vs Takeda's standalone investment in licensed compound. Cross-check: pure cash floor ($10.63) is 67% of FV — base case requires ~$5.20 of pipeline NPV to materialize, which Takeda is actively funding. Probability-weighted FV: 25%×$25 + 45%×$16 + 30%×$9 = $16.15 → consistent with $15.80 base. ⚠️ Not investment advice. Not investment advice.

warning

⚠️ Active class action investigations — TROPOS safety event

Multiple law firms (Pomerantz, Levi & Korsinsky, Kirby McInerney) opened investigations following the Dec 12, 2024 voluntary halt of dosing in certain arms of the Phase 2 TROPOS trial of cibotercept in PAH due to pericardial effusion adverse events. Stock dropped 16.51% to $10.42 on Jan 15, 2025. Risk: securities-fraud class action could result in settlement (typically $5-30M for biotech this size, well within cash position). Cibotercept program effectively de-prioritized. Monitor for class-period definition and lead plaintiff deadline.

check_circle

✅ Capital return completed — $375M returned to shareholders Oct 2025

Strategic review (triggered by ADAR1 Capital activism) resulted in $375M shareholder return: $181M Pontifax repurchase + $194M issuer tender offer, all at $17.75/share. Shares outstanding reduced ~35% to 19.79M. Board has demonstrated discipline — if pipeline disappoints, capital return remains a credible path. Cash retained ($281.5M) is sized to fully fund pipeline into 1H 2028.

⚠️ Methodology note: Clinical-stage biopharmaceutical with zero product revenue (FY25 was inflated by Takeda upfront license; FY26 ongoing burn). Fair value built on Cash Floor + risk-adjusted pipeline NPV (rNPV-lite). Peer comparison uses Price/Net Cash and EV vs pipeline rather than P/S — standard for pre-commercial biotech.

📊 Capital Structure · Short Interest · Buyback & Dilution

🟡 Short Interest

~8.5%

~1.7M shares short on 19.79M outstanding. Moderate level — reflects skepticism on pipeline + litigation overhang, not directional squeeze setup.

🟢 Share dilution (1Y)

−35%

From ~30.5M to 19.79M shares post Oct 2025 $375M capital return (Pontifax SPA + tender offer at $17.75/share). Aggressive shareholder-friendly action — very rare for biotech.

🟢 Buyback

$375M

$181M Pontifax negotiated repurchase + $194M issuer tender offer, both at $17.75/share, closed Oct-Nov 2025. Demonstrates board discipline on excess capital.

Short Interest — context

KROS — 8.5%

8.5%

Insider activity: Director Alpna Seth sold 2,625 shares at avg $10.72 on 2026-06-04 (small, <$30K). No material insider selling above the $500K threshold in the last 12 months. Director Mary Ann Gray received 7,142 RSUs and 7,433 stock options at $10.50 strike (June 2026), which sets a board-level reference point near the current price. Short interest moderate; tender at $17.75 acts as recent "voluntary purchase floor" memory but is not contractually repeating.

$Financial analysis — FY26 trajectory

Cash (Q1'26)

$281.5M

vs $287.4M FY25 close

Market cap

$204M

72% of cash

Net loss Q1'26

$23.7M

vs +$148.5M Q1'25 (Takeda upfront)

Cash runway

~1H 2028

~8 quarters at current burn

Item	FY2023	FY2024	FY2025	FY2026E	Guidance 2027
Revenue ($M)	0.3	1.2	200+ (Takeda)	~1-2	~5-10 (milestones)
R&D ($M)	102	155	~150	~80-90	~85-95
G&A ($M)	28	40	~50	~30-35	~30-35
Net loss ($M)	−122	−180	+5 (Takeda upfront)	~−95	~−110
Cash EoP ($M)	369	620	287	~210	~95-100

FY25 revenue inflated by Takeda upfront ($200M license agreement). True operational revenue minimal. Cash drop from $620M to $287M FY24→FY25 reflects $375M capital return + R&D burn. FY26E values are estimates; guidance not officially provided beyond cash runway statement (1H 2028).

Quarterly dynamics — last 5 quarters
Metric	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue ($M)	205.0	0.3	0.4	0.5	0.4
R&D spend ($M)	42.1	38.5	35.2	28.0	20.5
Net inc/loss ($M)	+148.5	−35.8	−40.2	−28.5	−23.7
Cash EoP ($M)	695	660	320	287	281.5

Financial position and sustainability

Cash / Market cap ratio

138%

Cash runway (months)

~24 mo

Net debt / EBITDA

Net cash

R&D efficiency (post-cut)

Moderate

account_tree

Business model — Activin/TGF-β biology platform

Clinical-stage biopharma focused on activin/TGF-β superfamily ligand traps

Keros develops therapeutics targeting the TGF-β family of proteins, which regulate red blood cell production, muscle/bone biology, and vascular function. Three lead assets: elritercept (anemia in MDS & myelofibrosis — licensed to Takeda Dec 2024, $200M upfront + milestones + royalties), rinvatercept/KER-065 (DMD, ALS — wholly owned, FDA orphan drug Aug 2025), and cibotercept (PAH — Phase 2 TROPOS partially halted Dec 2024 on safety, currently de-prioritized). Following the Oct 2025 capital return, the company runs a leaner operating model focused on internal rinvatercept progression while Takeda funds elritercept development.

Elritercept (Takeda partnership) ~$5-10M FY27E milestones 🟢 Ph3 active RENEW Ph3 MDS dosing started Jul 2025; Takeda planning Ph3 myelofibrosis. Keros retains Greater China rights + milestones/royalties. Most de-risked asset. Rinvatercept (KER-065) DMD/ALS $0 FY26 (pre-revenue) 🟡 Ph2 starting Wholly owned. Phase 2 DMD trial starting Q1 2026, ALS regulatory engagement 2H 2026. Ph1 healthy volunteers showed increased muscle mass + bone density, no DLTs. FDA orphan drug for DMD (Aug 2025). Cibotercept (PAH) $0 (paused) 🔴 Halted partial TROPOS Ph2 dosing in certain arms halted Dec 2024 over pericardial effusion. Class action driver. Repurposing path uncertain — option value but not base case.

Mechanism: rinvatercept acts as a ligand trap for myostatin and activin A (negative muscle/bone regulators), producing increases in muscle mass, bone mineral density and decreases in fat mass — relevant for DMD muscle preservation and ALS function. Elritercept addresses anemia via enhanced erythropoiesis, competing in MDS with Reblozyl (Bristol Myers Squibb) and in myelofibrosis with multiple anemia-focused programs. Takeda partnership de-risks the highest-value asset; rinvatercept represents the wholly owned upside.

gavel

Legal, regulatory and risk analysis

Active class action investigations (TROPOS)

High

Pomerantz, Levi & Korsinsky, Kirby McInerney all opened investigations on whether Dec 2024 TROPOS halt was adequately disclosed pre-event. Expected settlement range $5-30M (well within cash position). Lead plaintiff deadline not yet set. Settlement is a removable overhang.

Cash > Market cap (hard floor)

Positive

$281.5M cash vs $204M market cap = $77M negative EV. Even assuming 24 months of full burn ($190M), residual cash ($90M) provides ~$4.6/share floor. Real-world floor higher given board's demonstrated discipline on capital return.

Pipeline binary risk

Moderate

All assets are pre-approval. RENEW Ph3 MDS interim readouts (Takeda-led) could show efficacy or futility. Rinvatercept Ph2 DMD primary endpoints take 12-18 months. Any new safety signal (as occurred with cibotercept) could reset valuation.

Takeda contracted asset

Positive

Takeda funds elritercept Ph3 development (RENEW MDS active, myelofibrosis Ph3 planned). $200M upfront already received. Keros retains milestones, royalties, China rights. Highest-value asset is de-risked at the cash burn level.

Activist post-tender dynamics

Moderate

ADAR1 + Pontifax remain large holders post-$375M return; standstill agreements in place. If pipeline disappoints, second-round activist pressure for further capital return is plausible — could actually support the stock at this level.

SBC dilution

Low

Expected ~3-5% annual dilution from stock-based compensation. Material but bounded. No outstanding shelf utilization disclosed; board not signaling equity raise (cash sufficient).

Reblozyl (BMS) competitive threat

Moderate

Reblozyl is the established anemia therapy in MDS. Elritercept must demonstrate clear differentiation (efficacy in luspatercept-naive or refractory populations, broader label, better safety). Competitive moat will determine peak royalty potential to Keros.

DMD market — Sarepta competition

Moderate

DMD field crowded (Sarepta gene therapy, exon skippers, anti-myostatin programs). Rinvatercept must show functional benefit beyond muscle mass to justify peak sales. Orphan designation (Aug 2025) is supportive but not sufficient.

article

SWOT analysis

Strengths

+$281.5M cash, zero debt, runway into 1H 2028 — survives any single trial setback
+Takeda partnership de-risks highest-value asset, $200M upfront already received
+Board demonstrated discipline: $375M returned to shareholders Oct 2025 at $17.75
+Differentiated TGF-β biology platform with three independent indications
+FDA orphan drug designation for KER-065 in DMD (Aug 2025)

Weaknesses

−Zero product revenue; full dependence on burn-funded pipeline
−Cibotercept safety event (TROPOS halt) damaged credibility on safety screening
−Multiple class action investigations open — overhang removable only via settlement
−Clinical-stage biotech volatility: single readout can reset valuation ±50%

Opportunities

→RENEW Ph3 MDS positive interim could re-rate Keros to peer median 1.5x P/Cash → $20+
→Rinvatercept Ph2 DMD readouts could establish second franchise independent of Takeda
→Second-round capital return possible if internal programs underperform
→M&A optionality: Takeda or other strategics could acquire at premium to cash + Takeda asset

Threats

!New safety signal in any of rinvatercept Ph2 or elritercept Ph3 trials
!Class action settlement at high end of range ($25-50M) compresses cash floor
!Reblozyl entrenchment + new entrants compress elritercept peak share
!Biotech sector capital flows remain weak — re-rating may take longer

article

Summary by assessment area

🟢 Financial risk — LOW

$281.5M cash exceeds market cap by ~$77M
Zero debt, 8 quarters of runway
Board has demonstrated capital return discipline
FY26 burn ~$95M; FY27 ~$110M projected

🟡 Execution risk — MEDIUM

Pipeline binary: all assets pre-approval
Cibotercept halt is recent execution scar
Takeda partnership offloads elritercept execution risk
Rinvatercept Ph2 DMD is the next internal proving ground

🔴 Legal/governance — ELEVATED

Active class action investigations (multiple firms)
Expected settlement $5-30M — bounded
Activist holders + standstill agreements in place
No SEC investigation publicly disclosed

2026-08-13 earnings

Q2 2026 Earnings Release

short-term Impact: Medium Direction: Neutral

Cash burn pace verification (target ~$24M/qtr). Updated pipeline timeline. Any signal of capital allocation change (further return vs reinvest) will move the stock.

2026-09-30 product

Rinvatercept (KER-065) Phase 2 DMD first patient dosing

medium-term Impact: High Direction: Bullish

Formal Phase 2 entry validates the program advancement post-orphan designation. Re-rate signal: confirms execution and unlocks 12-18 month catalyst window into Ph2 readouts. Failure to enroll would re-rate cash floor only.

2026-11-30 regulatory

Rinvatercept ALS regulatory pathway alignment

medium-term Impact: Medium Direction: Bullish

Company-guided ALS regulatory engagement in 2H 2026. Could yield orphan designation, breakthrough designation, or trial design alignment — each incrementally positive. Optionality on second indication for rinvatercept.

2026-12-15 partnership

Takeda RENEW Ph3 MDS interim enrollment / safety update

medium-term Impact: High Direction: Binary

Takeda dosed first patient Jul 2025; ~18-month read-in possible by late 2026. Positive interim safety/enrollment update validates 40% PoS assumption. Any safety signal compresses Takeda asset value by ~half.

2027-03-31 partnership

Elritercept Phase 3 myelofibrosis trial initiation (Takeda-led)

long-term Impact: High Direction: Bullish

Takeda has stated plans to advance elritercept into Ph3 myelofibrosis (separate from RENEW MDS). Trial initiation triggers milestone payment to Keros and expands addressable market. Pipeline expansion catalyst.

2026-10-31 regulatory

TROPOS class action — lead plaintiff appointment / preliminary settlement signals

medium-term Impact: Medium Direction: Bullish

Any clarity on class period scope and settlement range removes overhang. Expected settlement $5-30M is bounded vs $281M cash. Resolution itself is bullish even at high end of range.

2027-01-31 capital_markets

Second-round capital return signal or strategic action

long-term Impact: High Direction: Bullish

If rinvatercept Ph2 underperforms or pipeline narrative slips, activist holders + board precedent suggest a second capital return event becomes plausible. Cash position ($210M end-FY26E) supports up to ~$100M additional return.

2027-06-30 M&A

M&A optionality — Takeda buy-in or strategic acquirer

long-term Impact: High Direction: Bullish

Trading below cash + Takeda-funded asset = textbook acquisition target. Takeda owns ex-China rights to elritercept; full acquisition could simplify. Other strategics interested in TGF-β/activin biology. Premium scenario: $20-25/share takeout.

Sources & Disclaimer

Sources: SEC filings (8-K, 10-Q FY26 Q1, DEF 14A 2026), Keros IR press releases (Jul 2025 RENEW dosing, Oct 2025 capital return), BioSpace, Stocktitan, Yahoo Finance, Investing.com, Pomerantz / Levi & Korsinsky / Kirby McInerney announcements, GlobalNewswire, MDA Conference 2026, FDA orphan drug grant Aug 2025, GuruFocus insider transactions. Market data — last verified close 2026-06-05: KROS ~$10.30, market cap ~$204M, 52W: $9.79–$22.55, 19.79M shares outstanding (per April 2026 proxy). Short interest ~8.5% (estimated). Q1 2026 cash $281.5M, runway into 1H 2028. ⚠️ This document is for informational purposes only and does not constitute financial or investment advice.